news
Antibody cocktail shown to neutralise SARS-CoV-2 variants of concern
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
List view / Grid view
Antibodies
news
Nanobody cocktail shown to block SARS-CoV-2 infection in mouse models
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
whitepaper
Brochure: NEW! Upgradeable label-free biomolecular analysis
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
news
Molecule in body that blocks antibody binding to SARS-CoV-2 discovered
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
news
SARS-CoV-2 infection induces polyfunctional antibodies, study finds
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
whitepaper
Catalogue: Drug target reagents
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
article
Targeting TNF to treat Dupuytren’s disease, frozen shoulder and POCD
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
news
Machine learning method to design better antibody drugs developed
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
news
Self-assembling nanofibres could prevent damage from inflammation
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
webinar
Imaging Mass Cytometry™ of malignant tissue architecture: rare single cells to structured multi-cellular communities
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
whitepaper
Article: Defeating COVID-19: The science behind a new ELISA
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
whitepaper
Article: Multisystem inflammatory syndrome in children with COVID-19
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
article
Fighting HIV: could antibodies be the answer?
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
